Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y
12 receptor (IC
50 = 100 nM).
1,2 Clopidogrel inhibits ADP-
induced platelet aggregation
ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite
via CYP2C19 in the liver enables its anti-
aggregating activity.
3 Marketed under the name Plavix
?, clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-
related metabolism.
4
![(R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride](https://www.chemicalbook.com/CAS/20180906/GIF/130209-90-4.gif)